NSIV Newsletter – February 2019 Find out more about: NSIV Member Spotlight – New England Hydropower IVIVA Adds a Senior Scientist NSIV By the Numbers seqWell in the News A Cool Piece of History Read

NEHC, the New England Hydropower Company, was started in 2012 in response to an overlooked market sector within the renewable energy hydropower industry. “I was looking to do something new and innovative in renewable energy,”

NSIV Newsletter – January 2019 Find out more about: NSIV Member Spotlight – Lariat Biosciences Virtech Bio Graduates Fall Interns Present Yankee Swap In the News Read the newsletter in your browser or open it as a PDF.

Lariat Biosciences Spotlight It is no surprise that development investments into liquid biopsies has surged recently. They offer easily repeatable, noninvasive genetic characterization of cancers, even informing personalized treatment for later stage disease. However, the

NSIV Newsletter – November 2018 Find out more about: NSIV Member Spotlight – IVIVA Medical NSIV Markets Soft Landings Program Events, News and Updates Read the newsletter in your browser or open it as a PDF.

End-stage renal disease, or kidney failure, affects over 500,000 patients in the United States. A transplant is the only definitive treatment, yet most patients spend years on the waitlist with little hope of receiving a

NSIV Newsletter – October 2018 Find out more about: NSIV Member Spotlight –Inovotion InBIA Soft Landings Designation – Update Welcome Erica Pratt, New Lab Manager Tom is our IRONMAN Events, News and Updates Read the

“If I could describe INOVOTION in one sentence,” says Olivier Baverey, INOVOTION’s US representative; “it would be accelerating research in oncology, while minimizing costs and risk.” INOVOTION began operations in 2014, after 5 years of

Beverly-based incubator chosen as only international soft landings center in New England; Offers specialized services to foreign biotech and cleantech companies establishing US operations North Shore InnoVentures (NSIV) earned recognition as part of the global

For patients dealing with anxiety, depression, phobia, and other behavioral illnesses, even going out to see a therapist face-to-face can be a real barrier to treatment. iHope Network recognizes this: multiple studies find no-show rates

NSIV Newsletter – September 2018 Find out more about: Member Spotlight – iHope Network InBIA Soft Landing Designation Awarded New Faces at NSIV Other Highlights Events of Interest Read the newsletter in your browser or open it

NSIV Newsletter – August 2018 NSIV is one of the leading cleantech and biotech incubators in Massachusetts. Learn more about: Member Spotlight – HepatoChem Summer Interns Present Accomplishments NSIV Companies Making News Other News of

Once again, interns working at NSIV impressed us with all they accomplished, both for their companies and personally. At the August InnoVentures U, our summer interns made formal presentations before a group of 30, explaining

HepatoChem was founded as a company for metabolite production, hence the name — “Hepato” refers to the liver, which is the organ responsible for most of metabolism. The company provides a sort “chemical liver” for

July 2018 Find out more about: Getting to Know CEO Chris Ilsley Member Spotlight – Glycologix Five Words – Our Companies Do What? Around the World with NSIV Read the newsletter in your browser or open it as

New NSIV CEO & President, Chris Ilsley (say “ills lee”) has been with us for just over a month. We briefly introduced him to you in last month’s newsletter, but now it’s time for a

This month, we welcome back Glycologix, who recently rejoined NSIV.  At Glycologix, what began as a potential cure for wrinkles has evolved into what could become the first treatment on the market for a debilitating

NSIV member company, InsomniSolv, recently won Sanofi’s VivaTech 2018 “Sleep Challenge”, voted the winner over 21 other submissions. Founder, Peter Kelley, is developing a neurostimulator device to mitigate insomnia. Read about the “Sleep Challenge” and

June 2018 Find out more about: Welcome to New NSIV President & CEO Member Spotlight – Genomic Expression New Companies Join NSIV Summer Interns are Here! The World Cup Read the newsletter in your browser or open

Every year, $100 billion goes into standard cancer treatment, prescribed based on the cancer’s stage and tissue of origin. Patients receiving these treatments assume that they are being given the medicine they need, but the